Loading...
Effectiveness of Ledipasvir/Sofosbuvir and Predictors of Treatment Failure in Members with Hepatitis C Genotype 1: A Retrospective Cohort Study in a Medicaid Population
Kouris, George Hydery, Tasmina Greenwood, Bonnie C. Lavitas, Pavel Alper, Caroline J. Price, Mylissa K. Clements, Karen M. Lenz, Kimberly J. Jeffrey, Paul L.
Kouris, George
Hydery, Tasmina
Greenwood, Bonnie C.
Lavitas, Pavel
Alper, Caroline J.
Price, Mylissa K.
Clements, Karen M.
Lenz, Kimberly J.
Jeffrey, Paul L.
Citations
Altmetric:
Student Authors
Faculty Advisor
Academic Program
UMass Chan Affiliations
Document Type
Poster
Publication Date
2017-03-27
Subject Area
Collections
Embargo Expiration Date
Link to Full Text
Abstract
An evaluation of the effectiveness of HCV genotype 1 treatment with Harvoni® (ledipasvir/sofosbuvir) as measured by a sustained virological response (SVR) of 12 weeks in the MassHealth fee-for-service and Primary Care Clinician plan population. The analysis concluded that treatment was associated with a a high rate of SVR12, which means that Hepatitis C is not detected in the blood after 12 weeks.
Source
Year of Medical School at Time of Visit
Sponsors
Dates of Travel
DOI
10.13028/af0c-5q14
Permanent Link to this Item
PubMed ID
Other Identifiers
Notes
Presented at the Academy of Managed Care and Specialty Pharmacy Annual Conference 2017.
Funding and Acknowledgements
Corresponding Author
Related Resources
Related Resources
Repository Citation
Rights
© 2017 University of Massachusetts Medical School